Clinical Trials in Suresnes, France
113 recruiting
Showing 1–20 of 129 trials
Recruiting
Phase 1Phase 2
Study of AZD0516 as Monotherapy and in Combination in Participants With Metastatic Prostate Cancer
Metastatic Prostate Cancer
AstraZeneca177 enrolled52 locationsNCT07181161
Recruiting
Phase 2
Efficacy of Daily IV Administration of Dornase Alfa up to 14 Days Post Subarachnoid Hemorrhage on Functional Independence at 6 Months
SAH (Subarachnoid Hemorrhage)Delayed Cerebral IschemiaRuptured Aneurysm of Intracranial Artery
Fondation Ophtalmologique Adolphe de Rothschild304 enrolled6 locationsNCT06723717
Recruiting
Phase 3
A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy
Breast Cancer (Early Breast Cancer)
AstraZeneca4,300 enrolled711 locationsNCT05774951
Recruiting
Phase 3
A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)
Prostate CancerProstatic Neoplasms
Merck Sharp & Dohme LLC1,440 enrolled282 locationsNCT06925737
Recruiting
Phase 3
Trial of Acetylsalicylic Acid and Atorvastatin in Patients With Castrate-resistant Prostate Cancer
Prostate Cancer
Gustave Roussy, Cancer Campus, Grand Paris1,210 enrolled30 locationsNCT03819101
Recruiting
Patient Retrospective Outcomes (PRO)
Chronic Pain
Boston Scientific Corporation15,000 enrolled143 locationsNCT01550575
Recruiting
Not Applicable
Analysis of the Effectiveness and Safety of Lorlatinib in Untreated ALK-Positive NSCLC Patients in a French Real-World Context
ALK+ Non-Small-Cell Lung Carcinoma
Pfizer90 enrolled31 locationsNCT06487078
Recruiting
Phase 3
A Study to Learn About the Effects of Felzartamab Infusions on Adults With Immunoglobulin A Nephropathy (IgAN)
Immunoglobulin A Nephropathy (IgAN)
Biogen454 enrolled233 locationsNCT06935357
Recruiting
Phase 3
A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)
Metastatic Castration-resistant Prostate Cancer (mCRPC)Prostatic Neoplasms
Merck Sharp & Dohme LLC1,314 enrolled324 locationsNCT06136650
Recruiting
Phase 2Phase 3
A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Bevacizumab in Combination With Chemotherapy in Participants With Previously Untreated, Unresectable, or Metastatic Colorectal Cancer
Untreated, Unresectable, or Metastatic Colorectal Cancer
Bristol-Myers Squibb990 enrolled279 locationsNCT07221357
Recruiting
Phase 3
A Clinical Study of Belzutifan and Zanzalintinib in People With Recurrent Kidney Cancer Following Adjuvant Therapy (MK-6482-033)
Renal Cell Carcinoma
Merck Sharp & Dohme LLC904 enrolled105 locationsNCT07227402
Recruiting
Phase 2
An Open-label Study of JSB462 (Luxdegalutamide) in Combination With Abiraterone in Adult Male Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
Metastatic Hormone Sensitive Prostate Cancer
Novartis Pharmaceuticals150 enrolled65 locationsNCT06991556
Recruiting
Phase 3
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)
Non-small Cell Lung Cancer
AstraZeneca880 enrolled301 locationsNCT06692738
Recruiting
Antimicrobial Therapy for Difficult-to-treat Pseudomonas Aeruginosa
Pseudomonas aeruginosaPrognosisPseudomonas Infections+3 more
Centre Hospitalier Régional d'Orléans600 enrolled48 locationsNCT06738771
Recruiting
Phase 3
A Follow-up Study to Test Long-term Treatment With Nerandomilast in People With Pulmonary Fibrosis Who Took Part in a Previous Study With Nerandomilast
Progressive Pulmonary FibrosisIdiopathic Pulmonary Fibrosis
Boehringer Ingelheim1,700 enrolled371 locationsNCT06238622
Recruiting
Phase 3
A Study to Learn About the Investigational Medicine Called PF-06821497 (Mevrometostat) in Men With mCRPC Who Were Previously Treated With Abiraterone Acetate for Prostate Cancer (MEVPRO-1).
Metastatic Castrate Resistant Prostate Cancer (mCRPC)
Pfizer600 enrolled233 locationsNCT06551324
Recruiting
Phase 1Phase 2
Study of Anti-CEACAM5 ADC M9140 in Participants With Advanced Solid Tumors (PROCEADE PanTumor)
Pancreatic CancerGastric CancerNon-small Cell Lung Cancer (NSCLC)+2 more
EMD Serono Research & Development Institute, Inc.250 enrolled81 locationsNCT06710132
Recruiting
AFU Registry of the Therapeutic Management and Follow-up of Non-Muscle-Invasive Bladder Cancer
Non Muscle Invasive Bladder Cancer
Association Francaise d'Urologie8,000 enrolled44 locationsNCT05002556
Recruiting
Not Applicable
Analysis of Biological Characteristics of Advanced ALK-rearranged NSCLC
Non-small Cell Lung CancerALK Gene Rearrangement Positive
Groupe Francais De Pneumo-Cancerologie100 enrolled46 locationsNCT05122806
Recruiting
PRostate Olaparib Real World Evidence Study
Metastatic Castration-resistant Prostate Cancer
AstraZeneca300 enrolled65 locationsNCT06031805